Press Releases

AMERICAN BIOGENETIC SCIENCES AND TREVIGEN HAVE GENERATED A NEW WAY TO MEASURE DNA DAMAGE

The Companies Expand Monoclonal Antibody Collaboration
To Low Immunoreactivity Antigens For Use In DNA Damage And Repair

Copiague, New York - May 4, 2000 - American Biogenetic Sciences, Inc. (ABS) (OTCBB:MABA) and Trevigen, Inc. have jointly generated a new way to measure DNA damage. The companies have also expanded an agreement to jointly create new monoclonal antibodies for use in the development of drugs for the control of DNA damage.

The collaboration will combine the resources of ABS's patented antigen free technology for producing highly specific monoclonal antibodies with Trevigen's expertise in DNA damage and repair. The arrangement expands an ongoing relationship between the two companies which is focused on the genetic causes of, and treatments for cancer and aging. The program has already generated a valuable new way to measure DNA damage. When fully developed, the test will be sold by Trevigen to biomedical researchers involved in research on DNA damage and repair. ABS will receive a royalty on all commercial products developed from this collaboration as well as maintaining manufacturing rights for the antibodies.

Producing highly specific monoclonal antibodies to DNA adducts is especially difficult because the antigen itself is so similar to normal DNA. Utilizing the ABS patented antigen free system permits antibody production to antigens of demonstrated low immunogenicity.

"We are extremely pleased with the results we have gotten thus far using the ABS antigen free technology. They have essentially created a specific antibody against 'SELF'," said Michael T. Elliott, President of Trevigen. "This type of capability will be essential as researchers seek solutions for major medical concerns such as aging and cancer, where damage to DNA and the cells ability to repair this damage underlie a multitude of medical problems. We believe we have an important role to play at Trevigen, as the pivotal role of the genetic component in human disease becomes better understood."

"Our successful generation of such a difficult to produce monoclonal antibody for Trevigen is further evidence of the importance of our antigen free technology," said John S. North, President and CEO of ABS. "As the frontiers of genomic research are expanded, we believe this technology will be invaluable to both researchers and pharmaceutical and diagnostic companies. This collaboration with Trevigen is a tangible expression of our technologies' promise."

About American Biogenetic Sciences, Inc.
American Biogenetic Sciences, Inc., based in Copiague, N.Y., researches and develops diagnostic tests for cardio-pulmonary conditions and infectious diseases, as well as new treatments for neurological disorders including epilepsy, migraine, mania, Parkinson's disease and Alzheimer's disease. ABS also seeks out new technologies and conducts research and development through its Global Scientific Network in the United States, Europe, Israel, Russia and China.

Trevigen, Inc.
Trevigen, Inc., based in Gaithersburg, M.D., develops and produces state of the art products for biomedical research involving DNA damage and repair. The company has also patented and is developing MIDASTM, an advanced technology based on DNA mismatch repair enzymes for the detection of mutations in DNA. With MIDAS, researchers will be able to identify the DNA mutations responsible for a host of gene linked diseases more quickly and accurately than with competing technology, yet without the expense of exhaustive DNA sequencing. Trevigen is the recipient of multiple US government research grant awards involving DNA damage and repair and has developed and markets over 300 products for cancer, aging and related biomedical research on a world-wide basis.

Statements in this release that are not strictly historical are "forward looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, and should be considered as subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated. For further details and a discussion of these risks and uncertainties, see the Companys' Securities and Exchange Commission filings including its annual report on Form 10-K

 

 


American Biogenetic Sciences, Inc. 2000